Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
This new neoadjuvant combination of pembrolizumab plus ramucirumab was feasible, and anti-VEGF agents may enhance the effects of immune checkpoint inhibitors.
Authors
- Shogo Kumagai (ORCID: https://orcid.org/0009-0001-0895-6846)
- Hiroyoshi Nishikawa (ORCID: https://orcid.org/0000-0001-6563-9807)
- H Furuya (ORCID: https://orcid.org/0009-0007-8879-945X)
- Keiju Aokage (ORCID: https://orcid.org/0000-0003-3193-9646)
- Shohei Koyama (ORCID: https://orcid.org/0000-0002-6897-9417)
- Kotaro Nomura (ORCID: https://orcid.org/0009-0009-1487-6533)
- Masahiro Tsuboi (ORCID: https://orcid.org/0000-0003-3031-5807)
- Genichiro Ishii (ORCID: https://orcid.org/0000-0001-8637-3323)
- Takuo Hayashi (ORCID: https://orcid.org/0000-0002-8544-9370)
- Kiyotaka Yoh (ORCID: https://orcid.org/0000-0001-6928-357X)
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Miki Fukutani
- Tetsuro Taki (ORCID: https://orcid.org/0000-0001-8654-6896)
- Joji Samejima (ORCID: https://orcid.org/0000-0002-9615-7883)
- Tomohiro Miyoshi (ORCID: https://orcid.org/0000-0002-6311-0691)
- Kenta Tane (ORCID: https://orcid.org/0000-0002-7737-8277)
- Jun Matsubayashi (ORCID: https://orcid.org/0000-0001-7545-9332)
- Yoshihisa Shimada (ORCID: https://orcid.org/0000-0003-3811-6159)
- Norihiko Ikeda (ORCID: https://orcid.org/0000-0002-5141-8808)
Institutions
- Tokyo Medical University (JP)
- Juntendo University (JP)
- National Cancer Centre Japan (JP)
- Chiba Cancer Center (JP)
- Hiroshima University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1561
- Citations
- 9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.54